AllianceBernstein
XERS icon

AllianceBernstein’s Xeris Biopharma Holdings XERS Stock Holding History

AllianceBernstein’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Hold
145,336
– – ﹤0.01% 2468
2026
Q1 		$1.14M Buy
145,336
+506
+0.3% +$3.35K ﹤0.01% 2284
2025
Q4 		$1.14M Hold
144,830
– – ﹤0.01% 2283
2025
Q3 		$1.18M Hold
144,830
– – ﹤0.01% 2270
2025
Q2 		$676K Hold
144,830
– – ﹤0.01% 2492
2025
Q1 		$795K Buy
144,830
+13,260
+10% +$53.5K ﹤0.01% 2349
2024
Q4 		$446K Sell
131,570
-16,150
-11% -$51.9K ﹤0.01% 2689
2024
Q3 		$421K Hold
147,720
– – ﹤0.01% 2750
2024
Q2 		$332K Buy
147,720
+67,300
+84% +$136K ﹤0.01% 2876
2024
Q1 		$178K Hold
80,420
– – ﹤0.01% 2948
2023
Q4 		$189K Hold
80,420
– – ﹤0.01% 2990
2023
Q3 		$150K Buy
80,420
+9,970
+14% +$22.8K ﹤0.01% 3017
2023
Q2 		$185K Buy
70,450
+31,050
+79% +$79K ﹤0.01% 3000
2023
Q1 		$64.2K Hold
39,400
– – ﹤0.01% 3073
2022
Q4 		$52.4K Buy
39,400
+15,300
+63% +$21.6K ﹤0.01% 3170
2022
Q3 		$38K Buy
24,100
+10,300
+75% +$17K ﹤0.01% 3197
2022
Q2 		$21K Buy
+13,800
New +$29.1K ﹤0.01% 3207
2021
Q2 		– Sell
-35,100
Closed -$158K – 3421
2021
Q1 		$158K Hold
35,100
– – ﹤0.01% 3103
2020
Q4 		$173K Hold
35,100
– – ﹤0.01% 3026
2020
Q3 		$208K Hold
35,100
– – ﹤0.01% 2951
2020
Q2 		$93K Buy
35,100
+14,600
+71% +$50.8K ﹤0.01% 3111
2020
Q1 		$40K Hold
20,500
– – ﹤0.01% 3075
2019
Q4 		$145K Hold
20,500
– – ﹤0.01% 2985
2019
Q3 		$202K Buy
20,500
+3,200
+18% +$36K ﹤0.01% 2943
2019
Q2 		$198K Buy
+17,300
New +$182K ﹤0.01% 2974

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein's XERS Position: Q2 2026 in Review

AllianceBernstein held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 145,336 shares worth $843K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

AllianceBernstein first reported a position in XERS in Q2 2019 and has held it in 25 quarters since. The position peaked at $1.18M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • AllianceBernstein held 145,336 shares of Xeris Biopharma Holdings worth $843K as of Q2 2026.
  • AllianceBernstein left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2468 holding.
  • AllianceBernstein first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 25 quarters since.
  • AllianceBernstein's Xeris Biopharma Holdings position peaked at $1.18M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.